Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOTAL: Tislelizumab + TNT in LARC
NCT06940388Phase 2Recruiting
- Sponsor
- Baruch Brenner
- Start
- Jul 2025
- Primary completion
- Aug 2029
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of tislelizumab in rectal cancer, sponsored by Baruch Brenner. Started Jul 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06940388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06940388.